Home  >  News
you can get e-magazine links on WhatsApp. Click here
+ Font Resize -

US DoD awards $1.7 million research grant to MediWound to develop NexoBrid for US Army

Yavne, Israel
Saturday, February 19, 2022, 17:00 Hrs  [IST]

MediWound Ltd., a fully-integrated biopharmaceutical company, announced that the US Department of Defense (DoD), through the Medical Technology Enterprise Consortium (MTEC), has awarded MediWound a $1.7 million research project for the development of NexoBrid as a non-surgical solution for field-care burn treatment for the US Army (the "MTEC Research Project Award").

“We are privileged to join forces with the US DoD, supporting its goals of improving treatment outcomes and saving lives of service members who suffer traumatic burn injuries in the battlefield,” said Sharon Malka, chief executive officer of MediWound. "This non-dilutive funding provides important recognition of NexoBrid's merits as a non-surgical, easy-to-use, effective solution for eschar removal of severe burns and highlights its potential role in treating severe burn injuries in the field as early as the point of injury. We thank the US Army Medical Research and Development Command (USAMRDC) for the award and look forward to working with them to have NexoBrid available for military use by the US Army.”

“The military services require simple and effective non-surgical solutions to treat severe burn patients as close to point of injury as possible. MTEC is excited to support MediWound’s effort to advance an effective non-surgical debriding solution for far forward burn treatment to benefit U.S. service members. This work could result in a transformational change to the current standard of care of burn injuries,” stated Lauren Palestrini, PhD, MTEC Director of Research Programs.

The MTEC Research Project Award was granted by the DoD’s USAMRDC through MTEC, a biomedical technology consortium working to advance innovative medical solutions to keep military personnel healthy and fully operational.

Field solutions for severe burn treatment that are simple and effective enough to be used in a pre-hospital setting as early as the point of injury and requiring minimal preparation and training, are needed to ensure optimal outcomes to combat personnel. The MTEC Research Project Award includes $1.7 million of funding to support development activities of NexoBrid over the next 24 months as a non-surgical debriding solution to treat severe burn injuries in a pre-hospital setting.

The US Army Medical Research and Development Command is the Army’s medical materiel developer, with responsibility for medical research, development, and acquisition. USAMRDC produces medical solutions for the battlefield with a focus on various areas of biomedical research, including military infectious diseases, combat casualty care, military operational medicine, medical chemical, and biological defense.

The Medical Technology Enterprise Consortium is a biomedical technology consortium collaborating with multiple government agencies under a 10-year renewable Other Transaction Agreement with the US Army Medical Research and Materiel Command.

MediWound is a biopharmaceutical company that develops, manufactures, and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration.


Post Your commentsPOST YOUR COMMENT
* Name :     
* Email :    
  Website :  
Apollo Clinical Research
Copyright © 2016 Saffron Media Pvt. Ltd |